scholarly journals A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)

2017 ◽  
Vol 28 ◽  
pp. x142-x143 ◽  
Author(s):  
D. Fujimoto ◽  
T. Yokoyama ◽  
H. Yoshioka ◽  
Y. Demura ◽  
K. Hirano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Low Dose ◽  
Egfr Mutation ◽  
Phase Ii Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)

Lung Cancer ◽  
2019 ◽  
Vol 135 ◽  
pp. 175-180 ◽  
Author(s):  
Toshihide Yokoyama ◽  
Hiroshige Yoshioka ◽  
Daichi Fujimoto ◽  
Yoshiki Demura ◽  
Katsuya Hirano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Egfr Mutation ◽  
Phase Ii Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Starting Dose ◽  
First Line Treatment

First line treatment of advanced non-small cell lung cancer with doxetaxel and cis-platin: A multicenter phase II study

1997 ◽  
Vol 33 ◽  
pp. S236 ◽  
Author(s):  
N. Androulakis ◽  
C. Kourousis ◽  
S. Kakolyris ◽  
A.M. Dimopoulos ◽  
E. Papadakis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Multicenter Phase ◽  
First Line Treatment

A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 7073-7073 ◽  
Author(s):  
G. Giaccone ◽  
T. Lechevalier ◽  
N. Thatcher ◽  
E. Smit ◽  
M. Janmaat ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document